|
1
|
Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999-2005).
|
Diagn Microbiol Infect Dis
|
2006
|
3.21
|
|
2
|
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004).
|
Microb Drug Resist
|
2006
|
3.11
|
|
3
|
Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).
|
J Clin Microbiol
|
2004
|
2.64
|
|
4
|
Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.
|
J Clin Microbiol
|
2006
|
2.34
|
|
5
|
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).
|
J Clin Microbiol
|
2008
|
2.07
|
|
6
|
Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.
|
Antimicrob Agents Chemother
|
2013
|
1.98
|
|
7
|
LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
|
Diagn Microbiol Infect Dis
|
2007
|
1.80
|
|
8
|
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
|
J Antimicrob Chemother
|
2004
|
1.76
|
|
9
|
Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
|
J Antimicrob Chemother
|
2005
|
1.75
|
|
10
|
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
|
Int J Antimicrob Agents
|
2004
|
1.73
|
|
11
|
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
|
J Antimicrob Chemother
|
2004
|
1.70
|
|
12
|
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).
|
Diagn Microbiol Infect Dis
|
2006
|
1.67
|
|
13
|
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.
|
Diagn Microbiol Infect Dis
|
2004
|
1.63
|
|
14
|
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
|
Diagn Microbiol Infect Dis
|
2005
|
1.61
|
|
15
|
Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.
|
Antimicrob Agents Chemother
|
2012
|
1.55
|
|
16
|
Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6')-30/aac(6')-Ib': report from the SENTRY Antimicrobial Surveillance Program.
|
Antimicrob Agents Chemother
|
2004
|
1.51
|
|
17
|
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
|
Antimicrob Agents Chemother
|
2013
|
1.50
|
|
18
|
Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.
|
Diagn Microbiol Infect Dis
|
2009
|
1.45
|
|
19
|
Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
|
J Antimicrob Chemother
|
2012
|
1.40
|
|
20
|
Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
|
J Antimicrob Chemother
|
2010
|
1.38
|
|
21
|
Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?
|
Mem Inst Oswaldo Cruz
|
2006
|
1.34
|
|
22
|
Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001).
|
J Antimicrob Chemother
|
2003
|
1.34
|
|
23
|
Initial results from a longitudinal international surveillance programme for anidulafungin (2003).
|
J Antimicrob Chemother
|
2004
|
1.33
|
|
24
|
Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae.
|
Microb Drug Resist
|
2010
|
1.33
|
|
25
|
Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
|
Antimicrob Agents Chemother
|
2012
|
1.33
|
|
26
|
Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
|
Diagn Microbiol Infect Dis
|
2004
|
1.33
|
|
27
|
Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
|
Antimicrob Agents Chemother
|
2010
|
1.32
|
|
28
|
Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
|
J Clin Microbiol
|
2009
|
1.30
|
|
29
|
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value.
|
J Chemother
|
2013
|
1.29
|
|
30
|
Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
|
J Antimicrob Chemother
|
2006
|
1.27
|
|
31
|
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
|
Diagn Microbiol Infect Dis
|
2005
|
1.26
|
|
32
|
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
|
J Antimicrob Chemother
|
2004
|
1.26
|
|
33
|
LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.
|
Antimicrob Agents Chemother
|
2011
|
1.25
|
|
34
|
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
|
Antimicrob Agents Chemother
|
2007
|
1.24
|
|
35
|
Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates.
|
Int J Antimicrob Agents
|
2010
|
1.23
|
|
36
|
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).
|
Diagn Microbiol Infect Dis
|
2012
|
1.21
|
|
37
|
Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study.
|
J Antimicrob Chemother
|
2011
|
1.21
|
|
38
|
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
|
J Antimicrob Chemother
|
2007
|
1.21
|
|
39
|
The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009).
|
J Infect
|
2010
|
1.20
|
|
40
|
Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
|
Diagn Microbiol Infect Dis
|
2013
|
1.20
|
|
41
|
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.
|
J Antimicrob Chemother
|
2004
|
1.20
|
|
42
|
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).
|
Diagn Microbiol Infect Dis
|
2012
|
1.16
|
|
43
|
AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
|
Clin Infect Dis
|
2012
|
1.16
|
|
44
|
Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).
|
Int J Antimicrob Agents
|
2003
|
1.14
|
|
45
|
Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and nonfermentative Gram-negative bacilli.
|
Antimicrob Agents Chemother
|
2013
|
1.14
|
|
46
|
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
|
Antimicrob Agents Chemother
|
2012
|
1.13
|
|
47
|
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
|
J Clin Microbiol
|
2011
|
1.12
|
|
48
|
Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004).
|
Int J Antimicrob Agents
|
2006
|
1.12
|
|
49
|
Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).
|
Diagn Microbiol Infect Dis
|
2010
|
1.12
|
|
50
|
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
|
J Antimicrob Chemother
|
2006
|
1.12
|
|
51
|
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
|
J Antimicrob Chemother
|
2005
|
1.12
|
|
52
|
Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia.
|
Int J Antimicrob Agents
|
2010
|
1.11
|
|
53
|
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.
|
Diagn Microbiol Infect Dis
|
2013
|
1.10
|
|
54
|
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
|
Antimicrob Agents Chemother
|
2005
|
1.09
|
|
55
|
Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011).
|
J Chemother
|
2013
|
1.09
|
|
56
|
Emerging epidemic of metallo-beta-lactamase-mediated resistances.
|
Diagn Microbiol Infect Dis
|
2005
|
1.09
|
|
57
|
Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
|
Diagn Microbiol Infect Dis
|
2007
|
1.09
|
|
58
|
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
|
Diagn Microbiol Infect Dis
|
2005
|
1.08
|
|
59
|
Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.
|
Diagn Microbiol Infect Dis
|
2007
|
1.08
|
|
60
|
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
|
J Antimicrob Chemother
|
2009
|
1.07
|
|
61
|
Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000).
|
Diagn Microbiol Infect Dis
|
2002
|
1.07
|
|
62
|
Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates.
|
Diagn Microbiol Infect Dis
|
2004
|
1.07
|
|
63
|
Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.
|
Antimicrob Agents Chemother
|
2006
|
1.07
|
|
64
|
In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
|
Clin Infect Dis
|
2012
|
1.06
|
|
65
|
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
|
Diagn Microbiol Infect Dis
|
2006
|
1.06
|
|
66
|
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005).
|
Diagn Microbiol Infect Dis
|
2007
|
1.05
|
|
67
|
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
|
Int J Antimicrob Agents
|
2007
|
1.05
|
|
68
|
Linezolid surveillance results for the United States: LEADER surveillance program 2011.
|
Antimicrob Agents Chemother
|
2012
|
1.05
|
|
69
|
Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
|
Int J Antimicrob Agents
|
2005
|
1.05
|
|
70
|
Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
|
Antimicrob Agents Chemother
|
2010
|
1.04
|
|
71
|
Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).
|
Int J Antimicrob Agents
|
2009
|
1.04
|
|
72
|
Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program.
|
J Clin Microbiol
|
2006
|
1.04
|
|
73
|
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
|
Diagn Microbiol Infect Dis
|
2005
|
1.03
|
|
74
|
The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).
|
J Infect
|
2010
|
1.03
|
|
75
|
Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program.
|
Clin Infect Dis
|
2005
|
1.02
|
|
76
|
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
|
Diagn Microbiol Infect Dis
|
2005
|
1.02
|
|
77
|
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
|
Diagn Microbiol Infect Dis
|
2008
|
1.01
|
|
78
|
Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
|
Diagn Microbiol Infect Dis
|
2010
|
1.01
|
|
79
|
Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005-2008).
|
Braz J Infect Dis
|
2009
|
0.99
|
|
80
|
Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.
|
J Clin Microbiol
|
2013
|
0.99
|
|
81
|
Correlation of cefoxitin MICs with the presence of mecA in Staphylococcus spp.
|
J Clin Microbiol
|
2009
|
0.98
|
|
82
|
Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010).
|
Diagn Microbiol Infect Dis
|
2011
|
0.98
|
|
83
|
Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009).
|
Diagn Microbiol Infect Dis
|
2011
|
0.96
|
|
84
|
Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.
|
Antimicrob Agents Chemother
|
2014
|
0.96
|
|
85
|
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
|
Diagn Microbiol Infect Dis
|
2006
|
0.95
|
|
86
|
Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).
|
Diagn Microbiol Infect Dis
|
2010
|
0.95
|
|
87
|
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infections.
|
J Antimicrob Chemother
|
2008
|
0.95
|
|
88
|
Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.
|
Clin Infect Dis
|
2008
|
0.95
|
|
89
|
The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin.
|
Clin Infect Dis
|
2006
|
0.94
|
|
90
|
Oritavancin microbiologic features and activity results from the surveillance program in the United States.
|
Clin Infect Dis
|
2012
|
0.93
|
|
91
|
Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil.
|
Infect Control Hosp Epidemiol
|
2002
|
0.92
|
|
92
|
Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wells.
|
J Clin Microbiol
|
2007
|
0.92
|
|
93
|
Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program.
|
Clin Infect Dis
|
2012
|
0.92
|
|
94
|
Surveillance of dalbavancin potency and spectrum in the United States (2012).
|
Diagn Microbiol Infect Dis
|
2013
|
0.91
|
|
95
|
Susceptibility of Klebsiella spp. to colistin and polymyxin B: results from the SENTRY Antimicrobial Surveillance Program (2006-2009).
|
Int J Antimicrob Agents
|
2010
|
0.91
|
|
96
|
In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States.
|
Clin Infect Dis
|
2011
|
0.91
|
|
97
|
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.
|
J Clin Microbiol
|
2007
|
0.91
|
|
98
|
Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in Mexico: report from the SENTRY Antimicrobial Surveillance Program.
|
Microb Drug Resist
|
2009
|
0.90
|
|
99
|
Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates.
|
Antimicrob Agents Chemother
|
2009
|
0.89
|
|
100
|
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
|
Int J Antimicrob Agents
|
2007
|
0.89
|
|
101
|
In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.
|
Antimicrob Agents Chemother
|
2009
|
0.89
|
|
102
|
Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.
|
J Antimicrob Chemother
|
2010
|
0.89
|
|
103
|
Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
|
Diagn Microbiol Infect Dis
|
2006
|
0.89
|
|
104
|
Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
|
Diagn Microbiol Infect Dis
|
2007
|
0.89
|
|
105
|
Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
|
Diagn Microbiol Infect Dis
|
2009
|
0.88
|
|
106
|
Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
|
Diagn Microbiol Infect Dis
|
2008
|
0.88
|
|
107
|
Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.
|
Antimicrob Agents Chemother
|
2014
|
0.88
|
|
108
|
Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002).
|
Diagn Microbiol Infect Dis
|
2003
|
0.87
|
|
109
|
Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
|
Diagn Microbiol Infect Dis
|
2004
|
0.87
|
|
110
|
Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada.
|
Int J Antimicrob Agents
|
2009
|
0.87
|
|
111
|
Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010.
|
BMC Res Notes
|
2012
|
0.87
|
|
112
|
Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization.
|
Diagn Microbiol Infect Dis
|
2003
|
0.85
|
|
113
|
Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010).
|
Int J Antimicrob Agents
|
2013
|
0.85
|
|
114
|
Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States.
|
Diagn Microbiol Infect Dis
|
2011
|
0.85
|
|
115
|
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.
|
Diagn Microbiol Infect Dis
|
2012
|
0.85
|
|
116
|
Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions.
|
Int J Antimicrob Agents
|
2006
|
0.85
|
|
117
|
Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
|
Int J Antimicrob Agents
|
2011
|
0.84
|
|
118
|
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
|
Diagn Microbiol Infect Dis
|
2007
|
0.84
|
|
119
|
Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.
|
Antimicrob Agents Chemother
|
2008
|
0.84
|
|
120
|
Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.
|
Antimicrob Agents Chemother
|
2013
|
0.84
|
|
121
|
Evaluation of the susceptibility profiles, genetic similarity and presence of qnr gene in Escherichia coli resistant to ciprofloxacin isolated in Brazilian hospitals.
|
Braz J Infect Dis
|
2007
|
0.84
|
|
122
|
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.
|
Antimicrob Agents Chemother
|
2011
|
0.84
|
|
123
|
Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
|
Diagn Microbiol Infect Dis
|
2005
|
0.83
|
|
124
|
Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002).
|
Mem Inst Oswaldo Cruz
|
2005
|
0.83
|
|
125
|
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
|
Int J Antimicrob Agents
|
2005
|
0.83
|
|
126
|
Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
|
Diagn Microbiol Infect Dis
|
2006
|
0.82
|
|
127
|
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
|
Diagn Microbiol Infect Dis
|
2007
|
0.82
|
|
128
|
Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
|
Int J Antimicrob Agents
|
2004
|
0.81
|
|
129
|
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
|
Antimicrob Agents Chemother
|
2008
|
0.81
|
|
130
|
Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.
|
J Chemother
|
2013
|
0.81
|
|
131
|
Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011.
|
Diagn Microbiol Infect Dis
|
2012
|
0.81
|
|
132
|
Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.
|
Diagn Microbiol Infect Dis
|
2009
|
0.81
|
|
133
|
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
|
Diagn Microbiol Infect Dis
|
2012
|
0.80
|
|
134
|
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?
|
Diagn Microbiol Infect Dis
|
2006
|
0.80
|
|
135
|
Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000).
|
Diagn Microbiol Infect Dis
|
2002
|
0.80
|
|
136
|
Comparative activity of linezolid against respiratory tract infection isolates of Staphylococcus aureus: an 11-year report from the SENTRY Antimicrobial Surveillance Program.
|
Int J Antimicrob Agents
|
2011
|
0.80
|
|
137
|
Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
|
Diagn Microbiol Infect Dis
|
2005
|
0.80
|
|
138
|
Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
|
Braz J Infect Dis
|
2013
|
0.80
|
|
139
|
Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.
|
J Clin Microbiol
|
2007
|
0.80
|
|
140
|
Carbapenem susceptibility discords among Acinetobacter isolates.
|
Clin Infect Dis
|
2006
|
0.80
|
|
141
|
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
|
Diagn Microbiol Infect Dis
|
2005
|
0.79
|
|
142
|
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
|
Diagn Microbiol Infect Dis
|
2007
|
0.79
|
|
143
|
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
|
J Chemother
|
2012
|
0.79
|
|
144
|
Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
|
Int J Antimicrob Agents
|
2010
|
0.79
|
|
145
|
Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).
|
J Clin Microbiol
|
2006
|
0.79
|
|
146
|
Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis).
|
Diagn Microbiol Infect Dis
|
2005
|
0.78
|
|
147
|
Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections.
|
Antimicrob Agents Chemother
|
2008
|
0.78
|
|
148
|
Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
|
J Antimicrob Chemother
|
2012
|
0.78
|
|
149
|
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
|
Diagn Microbiol Infect Dis
|
2006
|
0.77
|
|
150
|
In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
|
Diagn Microbiol Infect Dis
|
2008
|
0.77
|
|
151
|
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
|
Diagn Microbiol Infect Dis
|
2004
|
0.77
|
|
152
|
Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying β-lactamases prevalent in the United States.
|
Microb Drug Resist
|
2014
|
0.77
|
|
153
|
Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011.
|
Diagn Microbiol Infect Dis
|
2013
|
0.77
|
|
154
|
The use of molecular typing to evaluate the dissemination of antimicrobial resistance among Gram-negative rods in Brazilian hospitals.
|
Braz J Infect Dis
|
2004
|
0.76
|
|
155
|
Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample.
|
Diagn Microbiol Infect Dis
|
2013
|
0.76
|
|
156
|
Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
|
Diagn Microbiol Infect Dis
|
2005
|
0.76
|
|
157
|
Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure.
|
Pediatr Infect Dis J
|
2016
|
0.76
|
|
158
|
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
|
Diagn Microbiol Infect Dis
|
2006
|
0.76
|
|
159
|
Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008).
|
Pathology
|
2010
|
0.76
|
|
160
|
Disk diffusion and MIC quality control ranges for BC-3205 and BC-3781, two novel pleuromutilin antibiotics.
|
J Clin Microbiol
|
2012
|
0.75
|
|
161
|
Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United States.
|
Diagn Microbiol Infect Dis
|
2003
|
0.75
|
|
162
|
Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
|
Diagn Microbiol Infect Dis
|
2005
|
0.75
|
|
163
|
Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
|
Diagn Microbiol Infect Dis
|
2009
|
0.75
|
|
164
|
Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
|
Diagn Microbiol Infect Dis
|
2004
|
0.75
|
|
165
|
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
|
Pediatr Infect Dis J
|
2017
|
0.75
|
|
166
|
Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content.
|
Int J Antimicrob Agents
|
2005
|
0.75
|
|
167
|
Genotypic characterization of carbapenem-nonsusceptible Acinetobacter spp. isolated in Latin America.
|
Microb Drug Resist
|
2004
|
0.75
|
|
168
|
Ceftaroline Activity Tested against Bacterial Isolates Causing Community-Acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients from United States Hospitals: 2012-2014.
|
Pediatr Infect Dis J
|
2016
|
0.75
|
|
169
|
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
|
Diagn Microbiol Infect Dis
|
2013
|
0.75
|
|
170
|
Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae.
|
Diagn Microbiol Infect Dis
|
2006
|
0.75
|
|
171
|
Antimicrobial therapy for community-acquired pneumonia in adults.
|
Braz J Infect Dis
|
2002
|
0.75
|
|
172
|
In vitro activity of iclaprim and comparison agents tested against Neisseria gonorrhoeae including medium growth supplement effects.
|
Diagn Microbiol Infect Dis
|
2009
|
0.75
|
|
173
|
In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
|
Diagn Microbiol Infect Dis
|
2009
|
0.75
|
|
174
|
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.
|
Diagn Microbiol Infect Dis
|
2005
|
0.75
|